Controlling alpha in a clinical trial: the case for secondary endpoints
Open Access
- 10 March 2000
- journal article
- editorial
- Published by Wiley in Statistics in Medicine
- Vol. 19 (6) , 763-766
- https://doi.org/10.1002/(sici)1097-0258(20000330)19:6<763::aid-sim517>3.0.co;2-8
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Carvedilol and the Food and Drug Administration (FDA) Approval Process: The FDA Paradigm and Reflections on Hypothesis TestingControlled Clinical Trials, 1999
- End-Point Interpretation in Clinical Trials: The Case for DisciplineControlled Clinical Trials, 1999
- Methodological advances and plans for improving regulatory success for confirmatory studiesStatistics in Medicine, 1998
- Secondary endpoints can be validly analyzed, even if the primary endpoint does not provide clear statistical significanceControlled Clinical Trials, 1997
- Statistical Considerations for Multiplicity in Confirmatory ProtocolsDrug Information Journal, 1996
- Strategies for Dealing with Multiple Treatment Comparisons in Confirmatory Clinical TrialsDrug Information Journal, 1993
- Multiple comparisons in over‐the‐ounter drug clinical trials with both positive and placebo controlsStatistics in Medicine, 1991
- A sharper Bonferroni procedure for multiple tests of significanceBiometrika, 1988